- Home
- BFRI vs RNAZ Comparison
BFRI vs RNAZ Comparison
Compare BFRI & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- RNAZ
- Stock Information
- Founded
- BFRI 1997
- RNAZ 2016
- Country
- BFRI United States
- RNAZ United States
- Employees
- BFRI N/A
- RNAZ N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- RNAZ Health Care
- Exchange
- BFRI Nasdaq
- RNAZ Nasdaq
- Market Cap
- BFRI 8.7M
- RNAZ 7.2M
- IPO Year
- BFRI 2021
- RNAZ 2021
- Fundamental
- Price
- BFRI $0.80
- RNAZ $0.56
- Analyst Decision
- BFRI Strong Buy
- RNAZ Strong Buy
- Analyst Count
- BFRI 1
- RNAZ 1
- Target Price
- BFRI $7.00
- RNAZ $20.00
- AVG Volume (30 Days)
- BFRI 90.7K
- RNAZ 16.6M
- Earning Date
- BFRI 03-21-2025
- RNAZ 05-14-2025
- Dividend Yield
- BFRI N/A
- RNAZ N/A
- EPS Growth
- BFRI N/A
- RNAZ N/A
- EPS
- BFRI N/A
- RNAZ N/A
- Revenue
- BFRI $37,321,000.00
- RNAZ N/A
- Revenue This Year
- BFRI $28.62
- RNAZ $180.81
- Revenue Next Year
- BFRI $27.07
- RNAZ N/A
- P/E Ratio
- BFRI N/A
- RNAZ N/A
- Revenue Growth
- BFRI 9.54
- RNAZ N/A
- 52 Week Low
- BFRI $0.65
- RNAZ $0.43
- 52 Week High
- BFRI $2.43
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- BFRI 34.75
- RNAZ 27.66
- Support Level
- BFRI $0.81
- RNAZ $0.43
- Resistance Level
- BFRI $0.96
- RNAZ $0.67
- Average True Range (ATR)
- BFRI 0.08
- RNAZ 0.17
- MACD
- BFRI -0.01
- RNAZ 0.19
- Stochastic Oscillator
- BFRI 8.79
- RNAZ 4.75
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.